Srivichaivejvivat Future Growth
Future criteria checks 2/6
Srivichaivejvivat is forecast to grow earnings and revenue by 3.6% and 7.6% per annum respectively. EPS is expected to grow by 2.1% per annum. Return on equity is forecast to be 9.5% in 3 years.
Key information
3.6%
Earnings growth rate
2.1%
EPS growth rate
Healthcare earnings growth | 9.4% |
Revenue growth rate | 7.6% |
Future return on equity | 9.5% |
Analyst coverage | Low |
Last updated | 13 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 3,435 | 361 | -245 | 601 | 1 |
12/31/2025 | 3,168 | 388 | -1,198 | 594 | 1 |
12/31/2024 | 2,969 | 340 | 374 | 517 | 1 |
9/30/2024 | 2,883 | 342 | 329 | 528 | N/A |
6/30/2024 | 2,876 | 335 | 253 | 503 | N/A |
3/31/2024 | 2,826 | 317 | 167 | 442 | N/A |
12/31/2023 | 2,761 | 284 | 105 | 384 | N/A |
9/30/2023 | 2,673 | 248 | 333 | 636 | N/A |
6/30/2023 | 2,677 | 252 | 672 | 920 | N/A |
3/31/2023 | 2,970 | 363 | 176 | 714 | N/A |
12/31/2022 | 3,662 | 697 | 337 | 940 | N/A |
9/30/2022 | 3,754 | 694 | 1,122 | 1,713 | N/A |
6/30/2022 | 5,181 | 1,461 | 740 | 1,336 | N/A |
3/31/2022 | 5,394 | 1,565 | 1,408 | 1,681 | N/A |
12/31/2021 | 4,730 | 1,255 | 1,285 | 1,460 | N/A |
9/30/2021 | 4,551 | 1,260 | 232 | 410 | N/A |
6/30/2021 | 2,980 | 462 | 292 | 471 | N/A |
3/31/2021 | 2,320 | 203 | 177 | 365 | N/A |
12/31/2020 | 2,290 | 186 | 118 | 349 | N/A |
9/30/2020 | 2,331 | 177 | 229 | 429 | N/A |
6/30/2020 | 2,438 | 201 | 252 | 463 | N/A |
3/31/2020 | 2,537 | 208 | 225 | 458 | N/A |
12/31/2019 | 2,503 | 200 | 154 | 384 | N/A |
9/30/2019 | 2,417 | 169 | 25 | 279 | N/A |
6/30/2019 | 2,330 | 155 | 31 | 273 | N/A |
3/31/2019 | 2,282 | 170 | 24 | 261 | N/A |
12/31/2018 | 2,259 | 176 | 38 | 278 | N/A |
9/30/2018 | 2,225 | 181 | 53 | 302 | N/A |
6/30/2018 | 2,146 | 162 | N/A | 298 | N/A |
3/31/2018 | 2,081 | 145 | N/A | 252 | N/A |
12/31/2017 | 1,974 | 125 | N/A | 246 | N/A |
9/30/2017 | 1,917 | 116 | N/A | 234 | N/A |
6/30/2017 | 1,879 | 119 | N/A | 210 | N/A |
3/31/2017 | 1,809 | 137 | N/A | 230 | N/A |
12/31/2016 | 1,743 | 153 | N/A | 250 | N/A |
9/30/2016 | 1,648 | 157 | N/A | 300 | N/A |
6/30/2016 | 1,503 | 130 | N/A | 265 | N/A |
3/31/2016 | 1,433 | 119 | N/A | 263 | N/A |
12/31/2015 | 1,369 | 101 | N/A | 233 | N/A |
9/30/2015 | 1,315 | 88 | N/A | 139 | N/A |
6/30/2015 | 1,289 | 83 | N/A | 163 | N/A |
3/31/2015 | 1,287 | 91 | N/A | 141 | N/A |
12/31/2014 | 1,276 | 94 | N/A | 128 | N/A |
9/30/2014 | 1,235 | 82 | N/A | 162 | N/A |
6/30/2014 | 1,197 | 87 | N/A | 150 | N/A |
3/31/2014 | 1,160 | 71 | N/A | 147 | N/A |
12/31/2013 | 1,130 | 61 | N/A | 143 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VIH-R's forecast earnings growth (3.6% per year) is above the savings rate (2%).
Earnings vs Market: VIH-R's earnings (3.6% per year) are forecast to grow slower than the TH market (16.9% per year).
High Growth Earnings: VIH-R's earnings are forecast to grow, but not significantly.
Revenue vs Market: VIH-R's revenue (7.6% per year) is forecast to grow faster than the TH market (6.5% per year).
High Growth Revenue: VIH-R's revenue (7.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VIH-R's Return on Equity is forecast to be low in 3 years time (9.5%).